Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cimzia in Rheumatoid Arthritis (PreCePRA)
NCT01864265Phase 3Completed
- Sponsor
- FAU Erlangen-Nürnberg Medical Faculty
- Start
- Jul 2013
- Primary completion
- Jun 2019
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of certolizumab pegol in rheumatoid arthritis (RA), sponsored by FAU Erlangen-Nürnberg Medical Faculty. Started Jul 2013; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01864265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01864265.